Glucagon-like peptide–1–based medicines have weight loss–independent actions
Science
18 Jul 2024
Vol 385, Issue 6706
pp. 258-260
Abstract
Glucagon-like peptide–1 (GLP-1) is secreted from gut endocrine cells in response to food ingestion and acts as an incretin hormone to potentiate glucose-dependent insulin secretion. Pharmacological GLP-1 receptor (GLP- 1R) activation reduced glucagon secretion (which raises blood glucose) and gastric emptying, leading to the development of GLP-1 therapies for the treatment of type 2 diabetes (T2D). GLP-1R is expressed on several pancreatic islet cell types and within multiple regions of the central nervous system. Subsequent studies revealed that exogenous GLP-1 administration inhibited food intake through brain GLP-1R activation in animals and humans, leading to weight loss. The decades-long use of GLP-1 medicines, principally acylated peptides such as liraglutide and semaglutide, for the treatment of obesity and T2D (1) has revealed that they also exert pleiotropic actions beyond glucose and weight control, such as reduction of heart and kidney diseases. There are several potential mechanisms underlying these benefits, such as reducing systemic inflammation (2), which have implications for future clinical applications and drug development.
Access the full article
View all access options to continue reading this article.
References and Notes
1
D. J. Drucker, J. J. Holst, Diabetologia 66, 1765 (2023).
2
C. K. Wong et al., Cell Metab. 36, 130 (2024).
3
B. A. McLean, C. K. Wong, K. D. Kaur, R. J. Seeley, D. J. Drucker, JCI Insight 6, e153732 (2021).
4
K. C. Sourris et al., Kidney Int. 105, 132 (2024).
5
B. A. McLean et al., Endocr. Rev. 42, 101 (2021).
6
L. J. Lebrun et al., Cell Rep. 21, 1160 (2017).
7
B. Yusta et al., Diabetes 64, 2537 (2015).
8
C. K. Wong et al., Cell Metab. 34, 1514 (2022).
9
M. J. During et al., Nat. Med. 9, 1173 (2003).
10
J. Nowell, E. Blunt, P. Edison, Mol. Psychiatry 28, 217 (2023).
11
A. M. Lincoff et al., N. Engl. J. Med. 389, 2221 (2023).
12
W. Wang et al., Nat. Med. 30, 168 (2024).
13
W. Wang et al., Mol. Psychiatry 10.1038/s41380-024-02498-5 (2024).
14
L. Probst et al., JCI Insight 8, e170419 (2023).
15
M. K. Klausen et al., JCI Insight 7, e159863 (2022).